Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2200]

Are too many Phase III cancer clinical trials set up to fail?

Are too many Phase III cancer clinical trials set up to fail?

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

ESMO 2021: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

ESMO 2021: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced...

ESMO 2021: Update on INVICTUS trial shows improved overall median survival in GIST patients using ripretinib

ESMO 2021: Update on INVICTUS trial shows improved overall median survival in GIST patients using ripretinib

FDA approves cabozantinib for differentiated thyroid cancer

FDA approves cabozantinib for differentiated thyroid cancer

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20...

Study identifies new risk factor for most common childhood cancer, acute lymphoblastic leukaemia (ALL)

Study identifies new risk factor for most common childhood cancer, acute lymphoblastic leukaemia (ALL)

ESMO 2021: Oncology research rebounds from pandemic low, but shows cancer patients need special attention after COVID-19 recovery

ESMO 2021: Oncology research rebounds from pandemic low, but shows cancer patients need special attention after...

Legislation may help identify breast cancer earlier in certain at-risk women

Legislation may help identify breast cancer earlier in certain at-risk women

KRAS G12C inhibitor sotorasib receives conditional marketing authorisation by MHRA for use in Great Britain

KRAS G12C inhibitor sotorasib receives conditional marketing authorisation by MHRA for use in Great Britain

More from ecancer